Creates provisions relating to insurance coverage for prescription insulin drugs

This bill establishes a cap on the out-of-pocket costs for prescription insulin drugs, limiting enrollee expenses to a maximum of thirty dollars per thirty-day supply. It requires insurance plans to calculate these costs based on a drug price that has been reduced by at least the full amount of any rebates received from manufacturers or pharmacies. While the law mandates this rebate reduction for pricing calculations, it explicitly protects the specific details of these financial arrangements from public disclosure by classifying them as trade secrets. The provisions apply to health benefit plans that are issued, delivered, or renewed on or after January 1, 2025.